

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,027	03/26/2002	William E. Jack	NEB-166-PUS	9409
28986 75	986 7590 07/05/2006		EXAMINER	
HARRIET M. STRIMPEL; NEW ENGLAND BIOLABS, INC. 240 COUNTY ROAD			HUTSON, RICHARD G	
	IPSWICH, MA 01938-2723		ART UNIT	PAPER NUMBER
ŕ			1652	
			DATE MAILED: 07/05/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) **Advisory Action** 10/089.027 JACK ET AL. Before the Filing of an Appeal Brief **Art Unit** Examiner Richard G. Hutson 1652 --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 01 June 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires ____ months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on <u>09 May 2006</u>. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. X The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below): (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. Tor purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: 13 and 18. Claim(s) rejected: <u>1-12,14-17 and 19-31</u>. Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. A The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s), (PTO/SB/08 or PTO-1449) Paper No(s).

Richard G Hutson, Ph.D. **Primary Examiner**

Art Unit: 1652

13. ☐ Other: .

Application No. 10/089,027

Continuation of 3. NOTE: Applicants proposed amendment of claims 29 and 30 that would require that the DNA polymerase has been mutated so as to have an exonuclease activity of less than 5% or 25%, if entered would present a new issue after final rejection. Specifically the issue of enablement with regard to those mutations that result in a specific level of exonuclease activity relative to an unmodified enzyme would need to be further considered.

Continuation of 11. does NOT place the application in condition for allowance because:

The rejections of record remain for the reasons of record in light of the non-entry of applicants proposed amendment. Applicants submitted declaration has been considered in light of the current claim set and applicants arguments, however, is not persuasive in overcoming the rejections of record for the reasons previously stated and in light of the non-entry of applicants proposed amendment. Applicants arguments continue to be directed to a common structure shared by archaeon Family B DNA polymerases, however, it remains how this structure relates to the necessary limitation of the claimed methods.

The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to those archaeon DNA polymerases which must have the specifically discussed function (i.e. acyclonucleotide incorporation characteristic) necessary to practice the methods encompassed by the claims, including methods of use of all archaeon Family B DNA polymerase and variants thereof with such a functional characteristic..